This backbone achieves deep molecular responses in FLT3-mutant AML, with a 2024 trial reporting 65% CR/CRh rates with gilteritinib + venetoclax + azacitidine (Perl et al., 2019). This evidence concerns the gene FLT3 and acute myeloid leukemia.